|
gptkbp:instanceOf
|
immunosuppressant
|
|
gptkbp:approvedBy
|
gptkb:FDA
1994
|
|
gptkbp:ATCCode
|
L04AD02
|
|
gptkbp:bioavailability
|
20-25% (oral)
|
|
gptkbp:brand
|
gptkb:Prograf
gptkb:Advagraf
gptkb:Protopic
|
|
gptkbp:CASNumber
|
104987-11-3
|
|
gptkbp:category
|
immunosuppressant
macrolide lactone
|
|
gptkbp:chemicalFormula
|
C44H69NO12
|
|
gptkbp:contraindication
|
lactation
hypersensitivity to tacrolimus
|
|
gptkbp:discoveredBy
|
gptkb:Fujisawa_Pharmaceutical_Co.
|
|
gptkbp:discoveredIn
|
1987
|
|
gptkbp:drugInteraction
|
gptkb:milk
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:erythromycin
gptkb:ketoconazole
gptkb:St._John's_Wort
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:excretion
|
bile
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tacrolimus
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
|
gptkbp:metabolism
|
gptkb:CYP3A5
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
822.018 g/mol
|
|
gptkbp:origin
|
gptkb:Streptomyces_tsukubaensis
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
hypertension
nephrotoxicity
neurotoxicity
hyperglycemia
increased risk of infection
|
|
gptkbp:synonym
|
gptkb:FK506
gptkb:fujimycin
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of rheumatoid arthritis
treatment of atopic dermatitis
treatment of ulcerative colitis
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|